- Details
- Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients' goals and risk tolerance. Dr. Porten highlights the importance of discussing radical cystectomy as the gold standard while also considering bladder-preserving treatments depending on the patient's disease characteris...
|
- Details
- Ashish Kamat welcomes Petros Grivas to discuss the current state and future prospects of treating invasive bladder cancer with neoadjuvant chemotherapy or immunotherapy followed by local therapy. Dr. Grivas emphasizes the current standard of care involving neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy or chemoradiation. He highlights promising clinical trials, such as RET...
|
- Details
- Ashish Kamat hosts Paolo Gontero and Michael Cookson to discuss managing high-risk bladder cancer with variant histology. They address the challenges of treating these cases, given the variability in pathology reports and treatment strategies. Dr. Cookson emphasizes treating these patients as high-risk and the importance of proper staging and patient counseling. Dr. Gontero highlights the increase...
|
- Details
- Ashish Kamat is joined by Paramananthan (Param) Mariappan and Sarah Psutka. They discuss managing patients with low-grade intermediate-risk bladder cancer, focusing on treatment, surveillance, and de-escalation strategies. Dr. Psutka emphasizes the complex decision-making process and the need to understand patient priorities. She highlights the importance of discussing the likelihood of recurrence...
|
- Details
- Sam Chang speaks with Sandeep (Bobby) Reddy about the FDA-approved agent Anktiva combined with BCG for BCG-unresponsive non-muscle invasive bladder cancer. Dr. Reddy discusses the results from the QUILT 2.005 trial, showing high durability and response rates in patients. He explains the mechanism of Anktiva, which enhances immune response without increasing regulatory T cells, leading to significa...
|
- Details
- Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta. They highlight cisplatin-based chemotherapy as the traditional mainstay but shift focus to the EV-302 trial, which explores enfortumab vedotin (EV) and pembrolizumab (pembro) as a new first-line combination. Dr. Oualla explains the mechanisms and significant efficacy o...
|
- Details
- Ashish Kamat and Patrick Soon-Shiong delve into the current status and future prospects of Anktiva for bladder cancer. Dr. Soon-Shiong addresses concerns about the BCG shortage and the steps taken to ensure its availability through a partnership with the Serum Institute of India, which will provide both traditional and next-generation recombinant BCG. He explains that Anktiva is designed to be use...
|
- Details
- Ashish Kamat and Patrick Soon-Shiong explore the clinical development and FDA approval of Anktiva for bladder cancer. Dr. Soon-Shiong outlines the journey from initial studies in BCG-naive and BCG-unresponsive patients to approval. Anktiva, combined with BCG, shows high complete remission rates and prolonged duration of response, providing a significant advancement in bladder preservation. Dr. Soo...
|
- Details
- Ashish Kamat interviews Patrick Soon-Shiong about the approval of Anktiva for bladder cancer treatment. Dr. Soon-Shiong shares his journey from pancreatic surgery at UCLA to developing this innovative therapy. He emphasizes the need to activate the immune system, particularly natural killer (NK) cells, which play a crucial role in targeting cancer cells. Anktiva, an IL-15 based therapy, works syne...
|
- Details
- Diane Newman interviews Bilal Chughtai about an innovative patient-centered pelvic floor prolapse device developed by Cosm. Dr. Chughtai explains that the traditional method of pessary fitting is trial-and-error, which can be frustrating for patients. Cosm's new technology uses 3D printing to create custom-fitted pessaries based on precise measurements of the prolapse, offering a more tailored and...
|
